再鼎医药展示了ZL-1503针对IL-13和IL-31Rα的临床前数据，用于缓解特应性疾病中的瘙痒和减少炎症

by GOAI

由GOAI生成

Share To

分享到

Zai Lab has unveiled preclinical data indicating that its investigational bispecific antibody, ZL-1503, may offer rapid itch relief and reduce inflammation in atopic diseases. The findings, presented on April 18, 2026, highlight the potential of ZL-1503 to target both IL-13 and IL-31Rα pathways, which are associated with inflammatory and pruritic responses in conditions such as atopic dermatitis..

再鼎医药公布了临床前数据，表明其研究中的双特异性抗体ZL-1503可能在特应性疾病中提供快速止痒并减轻炎症。这些研究结果于2026年4月18日发布，强调了ZL-1503靶向IL-13和IL-31Rα通路的潜力，这些通路与特应性皮炎等疾病中的炎症和瘙痒反应相关。

The research demonstrated that ZL-1503 effectively inhibited signaling through these pathways in preclinical models. This dual mechanism of action reportedly led to a significant reduction in itch-related behaviors and markers of inflammation. These results suggest that ZL-1503 could address key symptoms of atopic diseases by simultaneously targeting two critical drivers of disease pathology.

研究表明，ZL-1503 在临床前模型中有效抑制了这些通路的信号传导。据报道，这种双重作用机制显著减少了与瘙痒相关的行为和炎症标志物。这些结果表明，ZL-1503 通过同时靶向疾病病理的两个关键驱动因素，可能缓解特应性疾病的主要症状。

Further studies will be needed to confirm these findings and evaluate the safety and efficacy of ZL-1503 in clinical settings..

还需要进一步的研究来证实这些发现，并评估ZL-1503在临床环境中的安全性和有效性。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

For any suggestion and feedback, please contact us.

如果有任何建议和反馈，请联系我们。

Date: April 18, 2026

日期：2026年4月18日

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

电子邮件地址

Author

作者

GOAI

GOAI

Related Post

相关文章